Shionogi & Co., Ltd.

2018/07/13: Flu diagnosis kit ‘BRIGHTPOC®Flu・Neo’launched in Japan
2018/07/10: Shionogi Regains Full Rights to Symproic® (naldemedine) in the US
2018/07/02: Shionogi Filed for the New Drug Application of Baloxavir Marboxil in Taiwan for the Treatment of Influenza
2018/06/26: FDA Accepts Baloxavir Marboxil New Drug Application and Grants Priority Review for the Treatment of Influenza
2018/06/20: Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
2018/06/20: Announcement about the Adjustment of the Conversion Value for Euro-Yen Denominated Convertible BondsMaturingin 2019
2018/06/14: Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea
2018/06/06: Shionogi Announces Upcoming Presentations at American Society for Microbiology Microbe Meeting
2018/05/31: Shionogi enters into a license and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
2018/05/18: Audio Webcasting of FY2017 Financial Results
2018/05/10: FY2017 Financial Results
2018/05/09: Notice regarding introduction of a Restricted Stock Compensation Plan and a change of compensation amount for Directors
2018/05/09: Shionogi to Announce Executive Appointment